lifestyle.thepointnews.com

Author: InnoCare Pharma

Preclinical Data of Novel B7-H3 ADC ICP-B794 Unveiled at 2026 AACR, Demonstrating Superior Anti-Tumor Activity and Safety

April 21, 2026
InnoCare Releases 2025 Results and Business Highlights, Achieving First Annual Profit

March 25, 2026
InnoCare Announces First Healthy Volunteer Dosed in Clinical Trial of Novel VAV1 Degrader ICP-538 in China

March 15, 2026
InnoCare’s next-generation TRKi Zurletrectinib Receives Priority Review for the Treatment of Pediatric Patients with Solid Tumors in China

March 1, 2026
InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China

February 12, 2026
InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China

February 11, 2026
Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology

January 29, 2026